Medlive Technology Co., Ltd.

SEHK:2192 Lagerbericht

Marktkapitalisierung: HK$6.3b

Medlive Technology Management

Management Kriterienprüfungen 2/4

We currently do not have sufficient information about the CEO.

Wichtige Informationen

Liping Tian

Geschäftsführender

CN¥4.8m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts35.8%
Amtszeit als Geschäftsführer11.6yrs
Eigentum des Geschäftsführers1.1%
Durchschnittliche Amtszeit des Managementskeine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder6.3yrs

Jüngste Management Updates

Recent updates

Investors Shouldn't Be Too Comfortable With Medlive Technology's (HKG:2192) Earnings

Oct 02
Investors Shouldn't Be Too Comfortable With Medlive Technology's (HKG:2192) Earnings

Pinning Down Medlive Technology Co., Ltd.'s (HKG:2192) P/E Is Difficult Right Now

Sep 27
Pinning Down Medlive Technology Co., Ltd.'s (HKG:2192) P/E Is Difficult Right Now

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Jul 04
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price

Apr 08
Medlive Technology Co., Ltd.'s (HKG:2192) Business Is Yet to Catch Up With Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Feb 20
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Jan 10
Are Medlive Technology Co., Ltd. (HKG:2192) Investors Paying Above The Intrinsic Value?

Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Sep 27
Medlive Technology Co., Ltd.'s (HKG:2192) Intrinsic Value Is Potentially 20% Below Its Share Price

Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Jul 10
Medlive Technology (HKG:2192) Is Reinvesting At Lower Rates Of Return

Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

May 11
Medlive Technology Co., Ltd. (HKG:2192) Shares Slammed 28% But Getting In Cheap Might Be Difficult Regardless

Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

May 02
Robust Earnings May Not Tell The Whole Story For Medlive Technology (HKG:2192)

Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 26
Results: Medlive Technology Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

Feb 06
Here's What's Concerning About Medlive Technology's (HKG:2192) Returns On Capital

There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Oct 31
There Are Reasons To Feel Uneasy About Medlive Technology's (HKG:2192) Returns On Capital

Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

Jul 14
Medlive Technology (HKG:2192) Could Be Struggling To Allocate Capital

These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Apr 03
These Analysts Just Made A Massive Downgrade To Their Medlive Technology Co., Ltd. (HKG:2192) EPS Forecasts

Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Feb 22
Is Medlive Technology Co., Ltd. (HKG:2192) Worth HK$9.5 Based On Its Intrinsic Value?

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Liping Tian im Vergleich zu den Einnahmen von Medlive Technology verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Jun 30 2024n/an/a

CN¥290m

Mar 31 2024n/an/a

CN¥266m

Dec 31 2023CN¥5mCN¥2m

CN¥242m

Sep 30 2023n/an/a

CN¥216m

Jun 30 2023n/an/a

CN¥189m

Mar 31 2023n/an/a

CN¥153m

Dec 31 2022CN¥7mCN¥2m

CN¥117m

Sep 30 2022n/an/a

CN¥83m

Jun 30 2022n/an/a

CN¥48m

Mar 31 2022n/an/a

CN¥44m

Dec 31 2021CN¥7mCN¥1m

CN¥41m

Sep 30 2021n/an/a

CN¥55m

Jun 30 2021n/an/a

CN¥70m

Mar 31 2021n/an/a

CN¥78m

Dec 31 2020CN¥816kCN¥816k

CN¥85m

Dec 31 2019CN¥756kCN¥756k

CN¥31m

Dec 31 2018CN¥736kCN¥736k

CN¥14m

Vergütung im Vergleich zum Markt: Liping's total compensation ($USD682.31K) is above average for companies of similar size in the Hong Kong market ($USD495.13K).

Entschädigung vs. Einkommen: Liping's compensation has been consistent with company performance over the past year.

Geschäftsführer

Liping Tian (57 yo)

11.6yrs

Amtszeit

CN¥4,839,000

Vergütung

Ms. Liping Tian is Chairwoman and Chief Executive Officer of Medlive Technology Co. Ltd. Ms. Tian has been Executive Director of Medlive Technology Co. Ltd since April 2013. She has been the executive dire...

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Liping Tian
Chairwoman & CEO11.6yrsCN¥4.84m1.1%
HK$ 68.9m
Lixin Tian
President10.9yrsCN¥2.14m0.27%
HK$ 17.1m
Lijun Tian
VP, Deputy Head of Medical Information Science Research Unit & Executive Director10.9yrsCN¥2.04m0.21%
HK$ 13.4m
Xin Zhou
VP & Executive Director6.3yrsCN¥673.00kkeine Daten
Richard L. Yeh
Independent Non-Executive Director3.8yrsCN¥120.00kkeine Daten
Eiji Tsuchiya
Non-Executive Director10.9yrskeine Datenkeine Daten
Jun Ma
Independent Non-Executive Director3.8yrsCN¥120.00kkeine Daten
Shan Wang
Independent Non-Executive Director3.8yrsCN¥120.00kkeine Daten
Kazutaka Kanairo
Non-Executive Director1.6yrskeine Datenkeine Daten

6.3yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrener Vorstand: 2192's board of directors are considered experienced (6.3 years average tenure).